India pressured by U.S. Congressional committee, Pfizer, over drug patents
On March 13, 2013, the U.S. House of Representative held a hearing on U.S.-India Trade Relations. Among the several topics under discussion were “the issuance of compulsory licenses, patent revocations, and other policies on pharmaceuticals” in India.